Gallina John E 4

What Happened

• John E. Gallina, a director of CVS Health Corp (CVS), was granted 1,447.504 deferred stock units on 2026-05-14. The units were valued at $97.15 each, for a total reported value of $140,625. The transaction is reported as an award/grant (code A) and is recorded as a derivative security.

Key Details

• Transaction date and filing: Grant dated 2026-05-14; Form 4 filed 2026-05-15 (filed the next day, which appears timely).
• Price and value: 1,447.504 units × $97.15 = $140,625 (unit price = market price at grant).
• Transaction type: Award/Grant of deferred stock units (derivative), not an open-market purchase or sale.
• Shares owned after transaction: Not specified in the information provided on this filing.
• Footnotes from the filing:
  • F1: Units consist of deferred stock units issued for deferral of a semi-annual retainer under the Issuer's non-employee director compensation policy (2017 Incentive Compensation Plan).
  • F2: Each deferred stock unit will convert into one share of common stock and be issued in the future, as elected by the reporting person.

Context

• These deferred stock units are compensation for a non-employee director and will convert to common shares in the future per the director’s election; they are routine director compensation and do not represent an open-market buy or sell. Such awards are common and reflect pay structure rather than an immediate trading signal.